Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Patients’ Characteristics
2.2. Treatment and Outcome for Secondary SGCs
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- RARECARENet. Available online: http://app.rarecarenet.eu (accessed on 12 December 2020).
- Östman, J.; Anneroth, G.; Gustafsson, H.; Tavelin, B. Malignant salivary gland tumours in Sweden 1960–1989—An epidemiological study. Oral Oncol. 1997, 33, 169–176. [Google Scholar] [CrossRef]
- Chiaravalli, S.; Guzzo, M.; Bisogno, G.; De Pasquale, M.D.; Migliorati, R.; De Leonardis, F.; Collini, P.; Casanova, M.; Cecchetto, G.; Ferrari, A. Salivary gland carcinomas in children and adolescents: The Italian TREP project experience: Salivary Gland Carcinoma in Children. Pediatr. Blood Cancer 2014, 61, 1961–1968. [Google Scholar] [CrossRef] [PubMed]
- Saku, T.; Hayashi, Y.; Takahara, O.; Matsuura, H.; Tokunaga, M.; Tokuoka, S.; Soda, M.; Mabuchi, K.; Land, C.E. Salivary gland tumors among atomic bomb survivors, 1950–1987. Cancer 1997, 79, 1465–1475. [Google Scholar] [CrossRef]
- Land, C.E.; Saku, T.; Hayashi, Y.; Takahara, O.; Matsuura, H.; Tokuoka, S.; Tokunaga, M.; Mabuchi, K. Incidence of salivary gland tumors among atomic bomb survivors, 1950–1987. Evaluation of Radiation-Related Risk. Radiat. Res. 1996, 146, 28–36. [Google Scholar] [CrossRef]
- Modan, B.; Chetrit, A.; Alfandary, E.; Tamir, A.; Lusky, A.; Wolf, M.; Shpilberg, O. Increased risk of salivary gland tumors after low-dose irradiation. Laryngoscope 1998, 108, 1095–1097. [Google Scholar] [CrossRef]
- Schneider, A.B.; Lubin, J.; Ron, E.; Abrahams, C.; Stovall, M.; Goel, A.; Shore-Freedman, E.; Gierlowski, T.C. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: Dose-response relationships. Radiat. Res. 1998, 149, 625–630. [Google Scholar] [CrossRef]
- Bassal, M.; Mertens, A.C.; Taylor, L.; Neglia, J.P.; Greffe, B.S.; Hammond, S.; Ronckers, C.M.; Friedman, D.L.; Stovall, M.; Yasui, Y.Y.; et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study. J. Clin. Oncol. 2006, 24, 476–483. [Google Scholar] [CrossRef]
- Verma, J.; The, B.S.; Paulino, A.C. Characteristics and outcome of radiation and chemotherapy-related mucoepidermoid carcinoma of the salivary glands. Pediatr. Blood Cancer 2011, 57, 1137–1141. [Google Scholar] [CrossRef]
- Zidar, N.; Gale, N.; Župevc, A.; Žargi, M. Salivary gland tumours as second neoplasms: Two cases and literature review. J. Laryngol. Otol. 2010, 124, 577–580. [Google Scholar] [CrossRef]
- Beal, K.P.; Singh, B.; Kraus, D.; Yahalom, J.; Portlock, C.; Wolden, S.L. Radiation-induced salivary gland tumors: A report of 18 cases and a review of the literature. Cancer J. 2003, 9, 467–471. [Google Scholar] [CrossRef]
- Védrine, P.O.; Coffinet, L.; Temam, S.; Montagne, K.; Lapeyre, M.; Oberlin, O.; Orbach, D.; Simon, C.; Sommelet, D. Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 s malignant neoplasms. Head Neck 2006, 28, 827–833. [Google Scholar] [CrossRef] [PubMed]
- Whatley, W.; Thompson, J.; Rao, B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol. Head Neck Surg. 2006, 134, 385–388. [Google Scholar] [CrossRef] [PubMed]
- Orlandi, E.; Iacovelli, N.A.; Bonora, M.; Cavallo, A.; Fossati, P. Salivary gland. Photon beam and particle radiotherapy: Present and future. Oral Oncol. 2016, 60, 146–156. [Google Scholar] [CrossRef] [PubMed]
- Adelstein, D.J.; Koyfman, S.A.; El-Naggar, A.K.; Hanna, E.Y. Biology and management of salivary gland cancers. Semin. Radiat. Oncol. 2012, 22, 245–253. [Google Scholar] [CrossRef]
- Paterson, N.J.; Ramadan, O. Radiation-induced parotid mucoepidermoid carcinoma: A systematic review. Otolaryngol. Open J. 2017, 3, 9–15. [Google Scholar]
- Armstrong, G.T.; Liu, W.; Leisenring, W.; Yasui, Y.; Hammond, S.; Bhatia, S.; Neglia, J.P.; Stovall, M.; Srivastava, D.; Robison, L.L. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J. Clin. Oncol. 2011, 29, 3056–3064. [Google Scholar] [CrossRef]
- Bhattacharyya, N.; Fried, M.P. Determinants of survival in parotid gland carcinoma: A population-based study. Am. J. Otolaryngol. 2005, 26, 39–44. [Google Scholar] [CrossRef]
- Orlandi, E.; Bonomo, P.; Ferella, L.; D’Angelo, E.; Maddalo, M.; Alterio, D.; Infante, G.; Bacigalupo, A.; Argenone, A.; Iacovelli, N.A.; et al. Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO—Head and Neck working group. Head Neck 2019, 41, 3684–3692. [Google Scholar] [CrossRef]
- Chowdhry, A.K.; McHugh, C.; Fung, C.; Dhakal, S.; Constine, L.S.; Milano, M.T. Second primary head and neck cancer after Hodgkin lymphoma: A population-based study of 44,879 survivors of Hodgkin lymphoma: Head and Neck Cancer After Hodgkin Lymphoma. Cancer 2015, 121, 1436–1445. [Google Scholar] [CrossRef]
- Boukheris, H.; Stovall, M.; Gilbert, E.S.; Stratton, K.L.; Smith, S.A.; Weathers, R.; Hammond, S.; Mertens, A.C.; Donaldson, S.S.; Armstrong, G.T.; et al. Risk of Salivary Gland Cancer Following Childhood Cancer: A Report From The Childhood Cancer Survivor Study. Int. J. Radiat. Oncol. 2013, 85, 776–783. [Google Scholar] [CrossRef] [Green Version]
- Bjordal, K.; Ahlner-Elmqvist, M.; Hammerlid, E.; Boysen, M.; Evensen, J.F.; Biorklund, A.; Jannert, M.; Westin, T.; Kaasa, S. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope 2001, 111, 1440–1452. [Google Scholar] [CrossRef] [PubMed]
- Atula, T.; Grénman, R.; Klemi, P.; Syrjänen, S. Human papillomavirus, Epstein–Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Oral Oncol. 1998, 34, 391–395. [Google Scholar] [CrossRef]
- Boukheris, H.; Ron, E.; Dores, G.M.; Stovall, M.; Smith, S.A.; Curtis, R.E. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: A population-based analysis. Cancer 2008, 113, 3153–3159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rutigliano, D.N.; Meyers, P.; Ghossein, R.A.; Carlson, D.L.; Kayton, M.L.; Kraus, D.; La Quaglia, M.P. Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma. J. Pediatr. Surg. 2007, 42, 9–13. [Google Scholar] [CrossRef] [PubMed]
- Locati, L.D.; Perrone, F.; Cortelazzi, B.; Lo Vullo, S.; Bossi, P.; Dagrada, G.; Quattrone, P.; Bergamini, C.; Potepan, P.; Civelli, E.; et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers: Androgen deprivation therapy in salivary gland cancers. Head Neck 2016, 38, 724–731. [Google Scholar] [CrossRef] [PubMed]
- Fushimi, C.; Tada, Y.; Takahashi, H.; Nagao, T.; Ojiri, H.; Masubuchi, T.; Matsuki, T.; Miura, K.; Kawakita, D.; Hirai, H.; et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann. Oncol. 2018, 29, 979–984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alfieri, S.; Granata, R.; Bergamini, C.; Resteghini, C.; Bossi, P.; Licitra, L.F.; Locati, L.D. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? Oral Oncol. 2017, 66, 58–63. [Google Scholar] [CrossRef]
- Locati, L.D.; Perrone, F.; Losa, M.; Mela, M.; Casieri, P.; Orsenigo, M.; Cortelazzi, B.; Negri, T.; Tamborini, E.; Quattrone, P.; et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009, 45, 986–990. [Google Scholar] [CrossRef]
- Skálová, A.; Vanecek, T.; Sima, R.; Laco, J.; Weinreb, I.; Perez-Ordonez, B.; Starek, I.; Geierova, M.; Simpson, R.H.; Passador-Santos, F.; et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol. 2010, 34, 599–608. [Google Scholar] [CrossRef]
- Skálová, A.; Vanecek, T.; Uro-Coste, E.; Bishop, J.A.; Weinreb, I.; Thompson, L.D.R.; de Sanctis, S.; Schiavo-Lena, M.; Laco, J.; Badoual, C.; et al. Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: A report of 17 cases. Am. J. Surg. Pathol. 2018, 42, 1445–1455. [Google Scholar] [CrossRef]
- Nakaguro, M.; Urano, M.; Ogawa, I.; Hirai, H.; Yamamoto, Y.; Yamaguchi, H.; Tanigawa, M.; Matsubayashi, J.; Hirano, H.; Shibahara, J.; et al. Histopathological evaluation of minor salivary gland papillary–cystic tumours: Focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. Histopathology 2020, 76, 411–422. [Google Scholar] [CrossRef] [PubMed]
- Corrêa, T.S.; Matos, G.D.R.; Segura, M.; dos Anjos, C.H. Second-line treatment of HER2-positive salivary gland tumor: Ado-trastuzumab emtansine (T-DM1) after progression on trastuzumab. Case Rep. Oncol. 2018, 11, 252–257. [Google Scholar] [CrossRef] [PubMed]
- Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D.M.; Hechtman, J.; Wei, G.; et al. What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol. 2016, 27, 920–926. [Google Scholar] [CrossRef] [PubMed]
- Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N. Engl. J. Med. 2018, 378, 731–739. [Google Scholar] [CrossRef]
- Moore, A.; Bar, Y.; Maurice-Dror, C.; Ospovat, I.; Sarfaty, M.; Korzets, Y.; Goldvaser, H.; Gordon, N.; Billan, S.; Gutfeld, O.; et al. Next-generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience. Head Neck 2020, 42, 599–607. [Google Scholar] [CrossRef]
- Locati, L.D.; Galbiati, D.; Calareso, G.; Alfieri, S.; Singer, S.; Cavalieri, S.; Bergamini, C.; Bossi, P.; Orlandi, E.; Resteghini, C.; et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer 2020, 126, 1888–1894. [Google Scholar] [CrossRef]
- Cohen, R.B.; Delord, J.-P.; Doi, T.; Piha-Paul, S.A.; Liu, S.V.; Gilbert, J.; Algazi, A.P.; Damian, S.; Hong, R.L.; Le Tourneau, C.; et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the phase 1b KEYNOTE-028 study. Am. J. Clin. Oncol. 2018, 41, 1083. [Google Scholar] [CrossRef]
- Simpson, J.R.; Thawley, S.E.; Matsuba, H.M. Adenoid cystic salivary gland carcinoma: Treatment with irradiation and surgery. Radiology 1984, 151, 509–512. [Google Scholar] [CrossRef]
- Ali, S.; Palmer, F.L.; Yu, C.; DiLorenzo, M.; Shah, J.P.; Kattan, M.W.; Patel, S.G.; Ganly, I. A predictive nomogram for recurrence of carcinoma of the major salivary glands. JAMA Otolaryngol. Neck Surg. 2013, 139, 698–705. [Google Scholar]
- Ali, S.; Palmer, F.L.; Yu, C.; DiLorenzo, M.; Shah, J.P.; Kattan, M.W.; Patel, S.G.; Ganly, I. Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. Ann. Surg. Oncol. 2014, 21, 637–642. [Google Scholar] [CrossRef]
- Karam, S.D.; Snider, J.W.; Wang, H.; Wooster, M.; Lominska, C.; Deeken, J.; Newkirk, K.; Davidson, B.; Harter, K.W. Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy. J. Radiat. Oncol. 2012, 1, 147–153. [Google Scholar] [CrossRef] [Green Version]
- Zwicker, F.; Roeder, F.; Hauswald, H.; Thieke, C.; Timke, C.; Schlegel, W.; Debus, J.; Münter, M.W.; Huber, P.E. Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. Head Neck 2011, 33, 1695–1702. [Google Scholar] [CrossRef] [PubMed]
- Ward, M.C.; Riaz, N.; Caudell, J.J.; Dunlap, N.E.; Isrow, D.; Zakem, S.J.; Dault, J.; Awan, M.J.; Vargo, J.A.; Heron, D.E.; et al. Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: A multi-institution cohort study by the MIRI collaborative. Int. J. Radiat. Oncol. Biol. Phys. 2018, 100, 586–594. [Google Scholar] [CrossRef] [PubMed]
- Jensen, A.D.; Nikoghosyan, A.; Ellerbrock, M.; Ecker, S.; Debus, J.; Münter, M.W. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: Acute toxicity and feasibility. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2011, 101, 383–387. [Google Scholar] [CrossRef] [PubMed]
- Jensen, A.D.; Poulakis, M.; Nikoghosyan, A.V.; Chaudhri, N.; Uhl, M.; Münter, M.W.; Jensen, A.D.; Poulakis, M.; Nikoghosyan, A.V.; Chaudhri, N.; et al. Re-irradiation of adenoid cystic carcinoma: Analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2015, 114, 182–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vischioni, B.; Dhanireddy, B.; Severo, C.; Bonora, M.; Ronchi, S.; Vitolo, V.; Fiore, M.R.; D’Ippolito, E.; Petrucci, R.; Barcellini, A.; et al. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. Radiother. Oncol. 2020, 145, 172–177. [Google Scholar] [CrossRef]
- Hayashi, K.; Hayashi, K.; Koto, M.; Ikawa, H.; Hagiwara, Y.; Tsuji, H.; Ogawa, K.; Kamada, T. Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. Radiother. Oncol. 2019, 136, 148–153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Orlandi, E.; Alfieri, S.; Simon, C.; Trama, A.; Licitra, L.; RARECAREnet Working Group. Treatment challenges in and outside a network setting: Head and neck cancers. Eur. J. Surg. Oncol. 2019, 45, 40–45. [Google Scholar] [CrossRef] [Green Version]
- Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Anzai, Y.; Brizel, D.M.; Bruce, J.Y.; Busse, P.M.; Caudell, J.J.; Cmelak, A.J.; et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2020, 18, 873–898. [Google Scholar] [CrossRef]
- Jensen, K.; Friborg, J.; Hansen, C.R.; Samsøe, E.; Johansen, J.; Andersen, M.; Smulders, B.; Andersen, E.; Nielsen, M.S.; Eriksen, J.G.; et al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. Radiother. Oncol. 2020, 151, 149–151. [Google Scholar] [CrossRef]
- Sood, S.; McGurk, M.; Vaz, F. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J. Laryngol. Otol. 2016, 130, S142–S149. [Google Scholar] [CrossRef] [PubMed]
- Terhaard, C.H.J.; Lubsen, H.; Rasch, C.R.N.; Levendag, P.C.; Kaanders, H.H.À.M.; Tjho-Heslinga, R.E.; van Den Ende, P.L.; Burlage, F.; Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int. J. Radiat. Oncol. 2005, 61, 103–111. [Google Scholar] [CrossRef] [PubMed]
- Hayashi, K.; Yamamoto, N.; Shirai, T.; Takeuchi, A.; Kimura, H.; Miwa, S.; Higuchi, T.; Abe, K.; Taniguchi, Y.; Aiba, H.; et al. Sequential histological findings and clinical response after carbon ion radiotherapy for unresectable sarcoma. Clin. Transl. Radiat. Oncol. 2017, 2, 41–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bergamini, C.; Locati, L.; Bossi, P.; Granata, R.; Alfieri, S.; Resteghini, C.; Imbimbo, M.; Fallai, C.; Orlandi, E.; Tana, S.; et al. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? Oral Oncol. 2016, 54, 54–57. [Google Scholar] [CrossRef] [PubMed]
Patient | Gender | Age at Primary Diagnosis | Year of First Diagnosis | Histology | Site and Stage | Treatment | RT Techniques/RT Volumes and Doses | Late Sequelae | Latent Time between Primary Tumor and SGCs |
---|---|---|---|---|---|---|---|---|---|
Patient 1 | F | 10 | 2000 | Medulloblastoma | Cerebellar vermis T3M0 (Chang system) High Risk (>1.5 cm2 residual disease) | Sequential high dose CT → Sx → > RT Vincristine and CCNU-based maintenance therapy | Conventional XRT Hyperfractionated accelerated RT (HART) Craniospinal axis: 39 Gy Posterior fossa: 60 Gy | Neurocognitive impairment Panhypopituitarism Bilateral hypoacusia | 16 years |
Patient 2 | M | 68 | 2008 | Undifferentiated carcinoma EBER-negative HPV-positive | Nasopharynx cT2N2c (AJCC VII ed) | Platinum-based CRT | IMRT Elective nodal volume: 50 Gy High risk volume: 70 Gy Conventional fractionation | Severe Xerostomia Dental alterations Moderate fibrosis | 10 years |
Patient 3 | M | 18 | 1985 | Nodular lymphocyte-predominant HL | Neck Stage IIA (Ann Arbor staging) | Neck Sx → RT | Conventional XRT: 40 Gy mantle field 45 Gy neck nodes | Chronic ischemic cardiomyopathy | 32 years |
Patient 4 | M | 40 | 1992 | Squamous cell carcinoma | Oropharynx | Tonsillectomy → RT | Conventional XRT Elective nodal volume: 45 Gy High risk volume: 60 Gy Conventional fractionation | Xerostomia Hypothyroidism | 23 years |
Patient 5 | F | 27 | 1975 | Papillary thyroid carcinoma | Thyroid (stage not available) | Total thyroidectomy> external beam RT | Conventional γ photon-based RT (Co60) 45 Gy | Xerostomia Moderate fibrosis | 41 years |
Patient 6 | M | 10 | 1997 | Sarcoma G3, NOS | Soft tissues of paramandibular area (locally advanced disease, stage not available) | Sx → CT(CEVAIE) → RT(44.8 Gy, 1.6 Gy twice a day) | Conventional XRT | Moderate fibrosis | 19 years |
Patient 7 | M | 8 | 1975 | HL | Neck Stage II (Ann Arbor staging) | CT→ RT | Conventional XRT | Moderate fibrosis | 37 years |
Patient 8 | F | 17 | 1985 | Undifferentiated Carcinoma (EBER unknown) | Nasopharynx (loco-regionally advanced disease, stage not available) | CT (Vincristine, Adriamycin and cyclophosphamide × 2 cycles) RT + concurrent adriamycin and cyclophosphamide × 4 cycles | Conventional XRT T and pathological nodes: 62 Gy Elective nodes: 40.2 Gy | Trisma Xerostomia Massive fibrosis ipoplasia mandibola | 34 years |
Patient 9 | M | 19 | 1993 | Undifferentiated carcinoma (EBER unknown) | Nasopharynx T4N1 (AJCC VII edition) | Exclusive RT | Conventional XRT | Neck fibrosis Facial asymmetry Sinonasal synechiae | 22 years |
Patient 10 | F | 12 | 2014 | HL | Neck Stage III (Ann Arbor staging) | CT (COPP/ABV × 6); RT above and under diaphragm (total dose 14.4 Gy). | Conventional XRT T and pathological nodes: 62 Gy, elective nodes: 40.2 Gy | - | 5 years |
Patient 11 | M | 3 | 1983 | HL | Neck Stage IV (Ann Arbor staging) for bone marrow infiltration | CT + RT | Conventional XRT 20 Gy | - | 31 years |
Patient 12 | M | 45 | 1993 | Undifferentiated carcinoma (EBER unknown) | Nasopharynx (stage unknown) | Induction cisplatin + 5-FU followed by exclusive RT | Conventional XRT | - | 19 years |
Patient 13 | M | 13 | 1963 | Lymphoma NOS | Supradiaphragmatic lymph nodes | RT above diaphragm | Conventional XRT mantle field (unknown total dose) | - | 50 years |
Patient | Age at Secondary Diagnosis | Year of SGC Diagnosis | Site and Stage | SGCs Histology | Molecular Analysis | Relationship between SGC Volume and Previous RT Doses and Target Volumes | Treatment of SGCs | Second Course of RT Techniques/RT Dose and Volume | Recurrence/Progression | Toxicity | Last Follow-Up Status | OS Time |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient 1 | 29 | 2016 | Parotid gland pT1 | Low Grade Polymorphous Adenocarcinoma | N.A. | Within initial treatment volume and marginal to high-dose volume | Sx (R1) → RT | Photon-based VMAT 64 Gy on parotid surgical bed | No | Buccal spasms | Alive NED | 36 months |
Patient 2 | 78 | 2018 | Parotid gland cT4 Unresectable disease | Salivary duct carcinoma AR+ | PIK3CA: p.E542K exon 9 (6% of DNA) HRAS: p.Q61R exon 3 (13% of DNA) HER-2 negative | Within elective volume and marginal high dose volume | ADT → palliative RT | Photon based VMAT 30 Gy to macroscopic parotid disease (3 Gy per fraction) | Local progression after 2 months | - | Dead ED | 13 months |
Patient 3 | 50 | 2017 | Right parotid gland cT4 Unresectable disease | Salivary duct carcinoma AR+ | HER-2 negative | Within initial treatment volume | ADT | Not delivered | Local progression and bone metastasis after 6 months | - | Alive ED | 24 months |
Patient 4 | 63 | 2015 | Right submandibular gland. Stage pT1N0 | Salivary duct carcinoma AR+ | HER-2 negative | Not applicable | Surgery for local disease. At diagnosis of metastatic disease chemotherapy (CBDCA/paclitaxel), followed by ADT | Not delivered | Metastatic disease (bone, mediastinal nodes, lung) 12 months after surgery for local disease Best response to systemic treatments: SD to chemotherapy, PR to ADT | - | Alive ED | 48 months |
Patient 5 | 68 | 2016 | Parotid pT3R2 (RP nodes radiologically positive) | Carcinoma ex pleomorphic adenoma AR− | NR4A3 negative | Marginal to target volume | Sx → RT | Photon based VMAT-SIB in 33 fractions 69.96 Gy on macroscopic disease+ 59.4 Gy RP nodes and I-II neck levels | No | Fibrosis Trismus Facial nerve disorder | Alive NED | 38 months |
Patient 6 | 27 | 2015 | Left parotid pT3 R2 | Low grade mucoepidermoid carcinoma | N.A. | Marginal to target volume | Sx → RT | Photon based VMAT-SEQ in 35fractions 70 Gy on residual disease 50 Gy on surgical bed | No | Trismus Facial nerve disorder | Alive NED | 48 months |
Patient 7 | 42 | 2012 | Submandibular cT4 (ipsilateral mandibular nerve involvement) Unresectable disease | Adenocarcinoma NOS AR+ | N.A. | Marginal to target volume | RT+ADT | Photon based VMAT-SEQ in 30fractions | Brain and bone Progression after 30 months | - | Dead ED | 36 months |
Patient 8 | 50 | 2019 | Left submandibular gland pT4R2pN1ECS+ Right submandibular gland pT4R2pN0 | Adenoid cystic carcinoma (solid variant) Basal cell adenocarcinoma | MYB negative (ACC) | Marginal to high-risk target volume, within elective volume Marginal to high-risk target volume | Sx | Not delivered | Stable disease at both sides | - | Alive ED | 4 months |
Patient 9 | 41 | 2016 | Minor salivary gland (Oropharynx)pT2R1N2bECS+ M1(bone) | Adenocarcinoma NOS AR+ | TP53: p.V216M exon 6 (13% of DNA) HER-2 negative | Not applicable | Sx → ADT | Not delivered | Bone lung brain progression after 25 months from surgery | Dead ED | 39 months | |
Patient 10 | 17 | 2019 | Parotid pT2 R2 | Low Grade Mucoepidermoid carcinoma | N.A. | Marginal to high-risk target volume, within elective volume | Sx → RT | CIRT 6 Gy > Proton therapy (59.4 Gy to parotid bed, 50.4 Gy to perineural path) | No | Trismus Xerostomia Facial and trigeminal nerve disorder | Alive NED | 11 months |
Patient 11 | 34 (23 thyroid cancer) | December, 2013 *2005: thiroidectomy and RAI for papillary ca | Parotid pT3R1 | ACC | NGS: no mutations ALK and ROS1 negative | Not applicable | Sx → RT | CIRT 68.8 Gy(RBE) (4.3 Gy(RBE) × 16 over 4 weeks) | Lung metastases 2 years after surgery for ACC Currently active surveillance of lung metastases | Trismus Xerostomia Facial and trigeminal nerve disorder | Alive ED | 72 months |
Patient 12 | 64 | 2012 | Left parotid M1 (lung) | Salivary duct carcinoma AR+ | NGS: BRCA2: p.A336T exon 10 (50% of DNA) | Not applicable | Chemotherapy | Not delivered | Bone, lung and brain progression | - | Alive ED | 65 months |
Patient 13 | 63 | 2013 | Right submandibular gland pT4a pN2b | Adenocarcinoma NOS AR+ | NGS: no mutations | Not applicable | Sx | Not delivered | Loco-regional, lung and pleural progression | - | Dead ED | 74 months |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Romanello, D.A.; Imamguliyeva, Z.; Cavalieri, S.; Vischioni, B.; Gandola, L.; Iannalfi, A.; Iacovelli, N.A.; Licitra, L.; Guzzo, M.; Piazza, C.; et al. Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. Cancers 2020, 12, 3769. https://doi.org/10.3390/cancers12123769
Romanello DA, Imamguliyeva Z, Cavalieri S, Vischioni B, Gandola L, Iannalfi A, Iacovelli NA, Licitra L, Guzzo M, Piazza C, et al. Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. Cancers. 2020; 12(12):3769. https://doi.org/10.3390/cancers12123769
Chicago/Turabian StyleRomanello, Domenico Attilio, Zulfiyya Imamguliyeva, Stefano Cavalieri, Barbara Vischioni, Lorenza Gandola, Alberto Iannalfi, Nicola Alessandro Iacovelli, Lisa Licitra, Marco Guzzo, Cesare Piazza, and et al. 2020. "Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era" Cancers 12, no. 12: 3769. https://doi.org/10.3390/cancers12123769